Connection Between Infectious Mononucleosis and Mast Cell Activation Syndrome
The provided evidence does not establish a direct connection between infectious mononucleosis (Epstein-Barr virus infection) and mast cell activation syndrome (MCAS). The available guidelines and research focus on MCAS diagnosis and management without identifying EBV or infectious mononucleosis as a trigger or associated condition.
What the Evidence Shows
EBV and Hyperinflammation (Not MCAS)
Recent research demonstrates that EBV infection triggers a distinct hyperinflammatory response characterized by elevated cytokines (IL-18, IL-27, TNF) and IFN-γ-induced chemokines, with expansion of CD38+HLA-DR+ T lymphocytes 1. However, this inflammatory pattern is associated with hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS)—not mast cell activation syndrome. These are fundamentally different pathophysiologic processes:
- HLH/MAS: T-cell and macrophage-driven hyperinflammation
- MCAS: Mast cell mediator release (histamine, tryptase, prostaglandin D2, leukotriene C4)
MCAS Triggers and Pathophysiology
The 2019 AAAAI guidelines define MCAS as episodic systemic anaphylaxis affecting at least 2 organ systems from mast cell mediator secretion 2. Viral infections are not listed among the recognized triggers or associated conditions for MCAS in the authoritative guidelines. MCAS is classified into:
- Primary MCAS: Clonal disorders with KIT mutations, hereditary α-tryptasemia
- Secondary MCAS: IgE-mediated allergic triggers, physical stimuli
- Idiopathic MCAS: No identified trigger or mutation 3, 4
Clinical Implications
Why This Matters
If a patient presents with both recent/active EBV infection and symptoms suggestive of mast cell activation:
Consider alternative diagnoses first: The hyperinflammatory response to EBV (fever, lymphadenopathy, fatigue) can mimic some MCAS symptoms but represents a different pathologic process 5
Look for true MCAS criteria: Episodic symptoms with documented elevation of mast cell mediators (serum tryptase increase during episodes, elevated urinary histamine metabolites, 11β-PGF2α, or LTE4) and response to antimediator therapy 2, 6
Rule out HLH/MAS if severe: If EBV infection is accompanied by severe systemic inflammation, cytopenias, or hemophagocytosis, consider HLH/MAS rather than MCAS 1
Common Pitfall
Do not conflate the allergic-type symptoms that can occur with various viral infections with true MCAS. MCAS requires specific diagnostic criteria including documented mediator elevation and response to mast cell-targeted therapy, not just symptom overlap 7, 8.
Bottom Line
Based on current evidence through 2024-2025, there is no established pathophysiologic or clinical link between infectious mononucleosis and mast cell activation syndrome. If both conditions appear to coexist, they should be evaluated and managed as separate entities with their respective diagnostic criteria.